Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.
Tirabrutinib monotherapy achieved a 67% overall response rate with durable effects in 48 patients with relapsed/refractory primary CNS lymphoma.
- Why it matters: Primary CNS lymphoma has a poor prognosis with limited treatment options, especially after relapse, highlighting the need for effective, targeted therapies.
- What they did: The phase 2 PROSPECT trial treated patients with R/R PCNSL using once-daily oral tirabrutinib at 480 mg, assessing response rates, safety, and duration of response.
- The result: The treatment led to rapid, sustained responses with manageable side effects, supporting tirabrutinib as a promising therapy for R/R PCNSL.